{"entity":{"id":"paper-middleton-nature","kind":"paper","name":"The National Lung Matrix Trial of personalized therapy in lung cancer","aka":[],"tldr":"Paper cited by one trial page, indexed on Europe PMC as PubMed record 32669708 and published in Nature; the citing page links this DOI, which is how the record was matched.","summary":"The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke 1-3. As this group represents around 20% of all patients with lung cancer, the discovery of stratified medicine options for tobacco-associated NSCLC is a high priority. Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents. Here we report the current outcomes of 19 drug-biomarker cohorts from the ongoing National Lung Matrix Trial, the largest umbrella trial in NSCLC. We use next-generation sequencing to match patients to appropriate targeted therapies on the basis of their tumour genotype. The Bayesian trial design enables outcome data from open cohorts that are still recruiting to be reported alongside data from closed cohorts. Of the 5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-matched therapy-including 14 that re-registered to the trial for a sequential trial drug. Despite pre-clinical data supporting the drug-biomarker combinations, current evidence shows that a limited number of combinations demonstrate clinically relevant benefits, which remain concentrated in patients with lung cancers that are associated with minimal exposure to tobacco smoke.\n\nIndexed on Europe PMC as PubMed record 32669708 (DOI 10.1038/s41586-020-2481-8). Matched by DOI alone: one trial page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Nature 2020","url":"https://doi.org/10.1038/s41586-020-2481-8"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/32669708/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/32669708"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["national-lung-matrix-trial"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nature"],"dependsOn":[],"notes":[],"journal":"Nature","year":2020,"doi":"10.1038/s41586-020-2481-8","pmid":"32669708","authors":"Middleton G, Fletcher P, Popat S, et al.","paperType":"observational","findings":[],"whatItMeans":"One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.","caveats":["Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper."]},"route":"/key-papers/paper-middleton-nature/","neighbours":{"trial":[{"id":"national-lung-matrix-trial","kind":"trial","name":"National Lung Matrix Trial","route":"/trials/national-lung-matrix-trial/"}],"journal":[{"id":"nature","kind":"journal","name":"Nature","route":"/journals/nature/"}]}}